|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2007
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:L01XE08
|
|
gptkbp:brand
|
gptkb:Tasigna
|
|
gptkbp:CASNumber
|
gptkb:641571-10-0
|
|
gptkbp:contraindication
|
hypokalemia
hypomagnesemia
|
|
gptkbp:discoveredBy
|
gptkb:Novartis
|
|
gptkbp:hasMolecularFormula
|
gptkb:C28H22F3N7O
|
|
gptkbp:hasSMILES
|
C1=CC=C(C=C1)C2=NC3=CC=CC=C3N=C2N4C=NC(=C4C5=CC=C(C=C5)F)C(=O)N
|
|
gptkbp:hasUNII
|
8N3DW7272P
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nilotinib
|
|
gptkbp:KEGGID
|
D08966
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521903
gptkb:DB04868
559230
644241
|
|
gptkbp:sideEffect
|
nausea
diarrhea
headache
pruritus
rash
QT prolongation
myelosuppression
|
|
gptkbp:synonym
|
gptkb:AMN107
|
|
gptkbp:target
|
gptkb:BCR-ABL
|
|
gptkbp:usedFor
|
gptkb:chronic_myeloid_leukemia
Philadelphia chromosome-positive CML
|
|
gptkbp:bfsParent
|
gptkb:Tasigna
|
|
gptkbp:bfsLayer
|
5
|